Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
12.08
-0.12 (-0.98%)
At close: Sep 11, 2026, 4:00 PM EDT
11.96
-0.12 (-0.99%)
After-hours: Sep 11, 2026, 4:10 PM EDT
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $296.02 million as of September 11, 2026. Its market cap has increased by 17.89% in one year.
Market Cap
296.02M
Enterprise Value
114.62M
1-Year Change
17.89%
Ranking
Category
Stock Price
$12.08
ChartMarket Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $296.02M, a decrease of -92.83%. That is a compound annual growth rate of -39.53%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 296.02M | -54.73% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Q32 Bio | 319.13M |
| Upstream Bio | 314.93M |
| Abeona Therapeutics | 313.37M |
| SAB Biotherapeutics | 311.17M |
| Agenus | 310.19M |
| Vanda Pharmaceuticals | 304.73M |
| InflaRx | 302.10M |
| Immuneering | 295.67M |